Clinical Trials Directory

Trials / Completed

CompletedNCT06207396

Characteristics of Spiking in Ghent: a Multicentric Prospective Observational Study..

Characteristics of Spiking in Ghent: A Multicentric Prospective Observational Study

Status
Completed
Phase
Study type
Observational
Enrollment
107 (actual)
Sponsor
University Hospital, Ghent · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Accepted

Summary

This study aims to document the incidence and characteristics of spiking in the Ghent region, both anamnestically and by toxicological analysis. Spiking will be analyzed by immunoassay testing and high-resolution screening according to the protocol in the laboratory of UZ Gent;

Detailed description

This study aims at objectivating and characterizing the patients with alleged spiking in the city of Ghent. Every patient who presents at one of the four (out of four) emergency departments of Ghent, with a suspicion of spiking (drink/food/needle-spiking included), will be offered to take part of this study. The study entails a list of questions for the patient regarding demographics, recent own medication/drug/alcohol use and experienced symptoms; whilst the caregiver (doctor/nurse) completes a questionnaire regarding symptoms at time of presentation. For a presentation within 48h after event, both blood and urine samples are requested from the patient. When presenting between 48h and 96h after the event, only urine samples are requested. On this samples, IA and LC-GCMS according to the UNODOC standards ("Guidelines for the Forensic analysis of drugs facilitating sexual assault and other criminal acts") to objectify exogenous products. On request of the patient, these results can be added to the medical file of the patient.

Conditions

Interventions

TypeNameDescription
DIAGNOSTIC_TESTserum and urine analysisSpiking will be analyzed by immunoassay testing and high-resolution screening

Timeline

Start date
2023-06-01
Primary completion
2025-03-31
Completion
2025-05-31
First posted
2024-01-17
Last updated
2026-01-07

Locations

4 sites across 1 country: Belgium

Source: ClinicalTrials.gov record NCT06207396. Inclusion in this directory is not an endorsement.